Array seems to have found support and could break upwards the next weeks, based solely upon on the StochRSI and the weekly moving average trend. Besides that the fundamentals also look good. Analysts are bullish on this stock:
Array BioPharma Inc. (NASDAQ:ARRY) should head towards $11.08 per share according to 6 Analysts in consensus. The higher price estimate target is at $15 according to the Analysts.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.